» Articles » PMID: 35606197

A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions

Abstract

Background & Aims: Disease activity and severity of eosinophilic esophagitis (EoE) dictate therapeutic options and management, but the decision-making process for determining severity varies among practitioners. To reduce variability in practice patterns and help clinicians monitor the clinical course of the disease in an office setting, we aimed to create an international consensus severity scoring index for EoE.

Methods: A multidisciplinary international group of adult and pediatric EoE researchers and clinicians, as well as non-EoE allergy immunology and gastroenterology experts, formed 3 teams to review the existing literature on histology, endoscopy, and symptoms of EoE in the context of progression and severity. A steering committee convened a 1-day virtual meeting to reach consensus on each team's opinion on salient features of severity across key clinicopathologic domains and distill features that would allow providers to categorize disease severity.

Results: Symptom features and complications and inflammatory and fibrostenotic features on both endoscopic and histologic examination were collated into a simplified scoring system-the Index of Severity for Eosinophilic Esophagitis (I-SEE)-that can be completed at routine clinic visits to assess disease severity using a point scale of 0-6 for mild, 7-14 for moderate, and ≥15 for severe EoE.

Conclusions: A multidisciplinary team of experts iteratively created a clinically usable EoE severity scoring system denominated "I-SEE" to guide practitioners in EoE management by standardizing disease components reflecting disease severity beyond eosinophil counts. I-SEE should be validated and refined using data from future clinical trials and routine clinical practice to increase its utilization and functionality.

Citing Articles

Endoscopic diagnosis and management of eosinophilic esophagitis.

Tanaka F, Sawada A, Tanaka S, Kohashi K, Fujiwara Y DEN Open. 2025; 5(1):e70063.

PMID: 39822952 PMC: 11736424. DOI: 10.1002/deo2.70063.


Assessment of Disease Activity in Eosinophilic Esophagitis: Is It Clinically Relevant or Simply an Amusement for Experts?.

Safroneeva E, Schoepfer A Inflamm Intest Dis. 2025; 10(1):10-17.

PMID: 39810959 PMC: 11731911. DOI: 10.1159/000542470.


Eosinophilic gastrointestinal diseases with overall gastrointestinal tract causing liver abscess in an older patient: a case report and literature review.

Ke Y, Jiang Y, Yuan Y, Chen Y, Huang J, Huang C BMC Geriatr. 2024; 24(1):945.

PMID: 39548381 PMC: 11566447. DOI: 10.1186/s12877-024-05541-w.


Treatment Preference Archetypes in Eosinophilic Esophagitis and Their Implications for Therapy.

Chang J, Brophy K, Ryan K, Rubenstein J, Dellon E, Wallner L Am J Gastroenterol. 2024; 120(1):173-181.

PMID: 39422324 PMC: 11695144. DOI: 10.14309/ajg.0000000000003133.


Utilizing a balloon sheath and miniprobe for diagnostic endoscopic ultrasound in eosinophilic esophagitis: a case series.

Rabinowitz S, Candava R, Kady B, Arostegui D, Grossman E Ultrasound J. 2024; 16(1):40.

PMID: 39167277 PMC: 11339230. DOI: 10.1186/s13089-024-00380-7.


References
1.
Lucendo A, Molina-Infante J, Arias A, von Arnim U, Bredenoord A, Bussmann C . Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3):335-358. PMC: 5415218. DOI: 10.1177/2050640616689525. View

2.
Hirano I, Collins M, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer A . RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology. 2018; 156(3):592-603.e10. DOI: 10.1053/j.gastro.2018.10.051. View

3.
Ma C, Bredenoord A, Dellon E, Alexander J, Biedermann L, Hogan M . Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. Gastrointest Endosc. 2022; 95(6):1126-1137.e2. DOI: 10.1016/j.gie.2022.01.014. View

4.
Cotton C, Woosley J, Moist S, McGee S, Iuga A, Shaheen N . Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score. Endoscopy. 2021; 54(7):635-643. DOI: 10.1055/a-1675-7860. View

5.
Hirano I, Collins M, Katzka D, Mukkada V, Falk G, Morey R . Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol. 2021; 20(3):525-534.e10. DOI: 10.1016/j.cgh.2021.04.022. View